Cybin to release phase 2 topline safety and efficacy data for cyb003 in major depressive disorder and host r&d briefing on november 30, 2023

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next generation psychedelic-based treatment options, today announced that it will host an r&d briefing on thursday, november 30, 2023, in new york city, at 10:00am et. institutional investors, analysts and company guests are cordially asked to save the date for this importan.
CYBN Ratings Summary
CYBN Quant Ranking